Cyclophosphamide

Acute Coryza, Retinoblastoma, Lymphoma, Large B-Cell, Diffuse + 20 more
Treatment
41 FDA approvals
20 Active Studies for Cyclophosphamide

What is Cyclophosphamide

CyclophosphamideThe Generic name of this drug
Treatment SummaryCyclophosphamide is a medication used to treat cancer, including lymphoma and leukemia. It must be processed in the liver to become an active form of chemotherapy. Side effects of the drug include hair loss, infertility, birth defects, and an increased risk of cancer. It is also used to shear sheep.
Cyclophosphamideis the brand name
image of different drug pills on a surface
Cyclophosphamide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cyclophosphamide
Cyclophosphamide
1959
75

Approved as Treatment by the FDA

Cyclophosphamide, otherwise called Cyclophosphamide, is approved by the FDA for 41 uses like Retinoblastoma and Glomerulonephritis .
Retinoblastoma
Glomerulonephritis
Lung Cancers
histiocytic lymphoma
Leukemia, Myelocytic, Acute
Non-Hodgkin's Lymphoma (NHL)
mixed-cell type lymphoma
Chronic Myeloid Leukemia (CML)
Adenocarcinoma of the Ovaries
Acute Lymphoblastic Leukemia (ALL)
Disseminated Neuroblastoma
Nephrotic syndrome with lesion of minimal change glomerulonephritis
Burkitt Lymphoma (BL)
Lymphocytic Lymphomas
Hodgkins Disease (HD)
Acute Myeloid Leukemia (AML)
Breast Cancer
Chronic Lymphocytic Leukemia (CLL)
Acute monocytic leukemia
Malignant Lymphomas
Multiple Myeloma (MM)
Hodgkin Disease
failure with corticosteroid therapy
Lung Cancer
Acute Myeloid Leukemia
Acute Coryza
Erythema Induratum
Neuroblastoma
Lymphoma, Non-Hodgkin
Acute Lymphoblastic Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid, Acute
Breast Cancer
Non-Hodgkin's Lymphoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lymphoma, Non-Hodgkin
Adenocarcinoma
Multiple Myeloma
Lymphoma, Large B-Cell, Diffuse
Chronic Lymphocytic Leukemia
Retinoblastoma

Effectiveness

How Cyclophosphamide Affects PatientsCyclophosphamide is a type of medication used to treat cancer. It works by adding chemicals called alkyl groups to DNA, which prevents the cells from dividing and stops them from growing. It also adds methyl or other alkyl groups to molecules that should not be there, which disrupts how DNA works and causes the cells to die. Alkylating agents are cell cycle-nonspecific, meaning they affect any cell at any stage of its life cycle.
How Cyclophosphamide works in the bodyAlkylating agents are drugs that prevent cancer cells from reproducing by damaging their DNA. They do this in three ways: by attaching alkyl molecules to the DNA, creating bonds between the atoms of the DNA, and causing the nucleotides to mispair. As a result of this damage, the DNA is unable to be copied, preventing further cancer cell growth.

When to interrupt dosage

The advised dosage of Cyclophosphamide is contingent upon the diagnosed condition, for example Lymphoma, Glomerulonephritis and Leukemia, Myelocytic, Acute. The measure of dosage varies depending on the administration technique (e.g. Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular or Powder, for solution - Intravenous) featured in the table below.
Condition
Dosage
Administration
Breast Cancer
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Leukemia, Lymphocytic, Chronic, B-Cell
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Hodgkin Disease
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Retinoblastoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lymphoma, Large B-Cell, Diffuse
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lymphoma, Non-Hodgkin
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Acute Myeloid Leukemia
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Acute Lymphoblastic Leukemia
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lung Cancer
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
failure with corticosteroid therapy
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lymphoma, Non-Hodgkin
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Erythema Induratum
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Chronic Lymphocytic Leukemia
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Multiple Sclerosis
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Glomerulonephritis
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Acute Coryza
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Lupus
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Leukemia, Myeloid, Acute
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous
Neuroblastoma
, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL
Oral, , Tablet - Oral, Tablet, Capsule, Capsule - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Parenteral, Powder, for solution - Parenteral, Intravenous; Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution, Injection, solution - Intravenous, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Warnings

Cyclophosphamide Contraindications
Condition
Risk Level
Notes
severely depressed bone marrow function
Do Not Combine
Urinary Bladder Neck Obstruction
Do Not Combine
There are 20 known major drug interactions with Cyclophosphamide.
Common Cyclophosphamide Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Cyclophosphamide.
Abetimus
Major
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Abetimus.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Cyclophosphamide.
Cyclophosphamide Toxicity & Overdose RiskCommon side effects of taking this drug include lowered white blood cell count, fever, hair loss, nausea, vomiting, and diarrhea.
image of a doctor in a lab doing drug, clinical research

Cyclophosphamide Novel Uses: Which Conditions Have a Clinical Trial Featuring Cyclophosphamide?

1165 active clinical trials are currently being conducted to examine the potential of Cyclophosphamide to treat Breast Cancer, Lymphocytic Lymphomas and Multiple Myeloma.
Condition
Clinical Trials
Trial Phases
Non-Hodgkin's Lymphoma
123 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4
Multiple Sclerosis
120 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Acute Myeloid Leukemia
274 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
Hodgkin Disease
3 Actively Recruiting
Not Applicable, Phase 1
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Lung Cancer
178 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
Lymphoma, Large B-Cell, Diffuse
0 Actively Recruiting
Chronic Lymphocytic Leukemia
143 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Acute Lymphoblastic Leukemia
120 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Adenocarcinoma
2 Actively Recruiting
Phase 2, Phase 1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
0 Actively Recruiting
Neuroblastoma
0 Actively Recruiting
Glomerulonephritis
1 Actively Recruiting
Phase 3
Leukemia, Myeloid, Acute
0 Actively Recruiting
Erythema Induratum
0 Actively Recruiting
failure with corticosteroid therapy
0 Actively Recruiting
Retinoblastoma
6 Actively Recruiting
Phase 2, Not Applicable, Phase 1
Lymphoma, Non-Hodgkin
2 Actively Recruiting
Phase 1
Breast Cancer
26 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Lupus
6 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Cyclophosphamide Reviews: What are patients saying about Cyclophosphamide?

5Patient Review
9/13/2010
Cyclophosphamide for Scleroderma Lung Disease
I've been on this medication for a short time, so it's hard to say if it's effective yet. I have noticed some hair loss and decreased appetite. When I do eat, I sometimes feel nauseous. It seems like my breathing is better, but the change has been very gradual.
4.7Patient Review
3/15/2011
Cyclophosphamide for Cancer of the Ovary
This medicine has been incredibly effective, moreso than I could have hoped. My doctors decided to try something new on my 8th battle with cancer, and I'm so glad they did. As a college student, it's important to me that I can still go to school and work while taking this medication. The nausea has been tough to deal with but it's better than chemotherapy by far.
4.7Patient Review
5/26/2008
Cyclophosphamide for Breast Cancer that has Spread to Another Part of the Body
4.3Patient Review
9/1/2012
Cyclophosphamide for Scleroderma Lung Disease
I took this medication to get my Lupus under control, and it was successful. However, I experienced some troubling side effects afterwards that required me to take another medication. Thankfully, my liver returned to normal a few months later.
4Patient Review
8/1/2008
Cyclophosphamide for Multiple Myeloma
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cyclophosphamide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is cyclophosphamide a chemo or immunotherapy?

"Cyclophosphamide is an alkylating chemotherapeutic agent that suppresses the immune system."

Answered by AI

What is the cyclophosphamide used for?

"Cyclophosphamide is a medication used to treat cancer in various parts of the body, including the ovaries, breast, blood and lymph system, nerves, and eyes. It is also used for treating multiple myeloma and skin tumors."

Answered by AI

Is cyclophosphamide a steroid?

"Cyclophosphamide is sometimes called a "steroid-sparing agent" because it has different side effects than prednisone."

Answered by AI

How cyclophosphamide is given?

"This medication can be administered in various ways depending on the diagnosis, including intravenously, orally in tablet form, or by injection into a muscle, the abdominal lining, or the lining of the lung."

Answered by AI

Clinical Trials for Cyclophosphamide

Have you considered Cyclophosphamide clinical trials? We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Have you considered Cyclophosphamide clinical trials? We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Have you considered Cyclophosphamide clinical trials? We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top